ABL.F - Abbott Laboratories

Frankfurt - Frankfurt Delayed Price. Currency in EUR
75.92
-0.31 (-0.41%)
As of 3:45PM CEST. Market open.
Stock chart is not supported by your current browser
Previous Close76.23
Open76.10
Bid73.80 x 90000
Ask74.11 x 90000
Day's Range75.92 - 76.10
52 Week Range56.36 - 80.00
Volume3
Avg. Volume181
Market Cap134.246B
Beta (3Y Monthly)0.37
PE Ratio (TTM)46.69
EPS (TTM)1.63
Earnings DateN/A
Forward Dividend & Yield1.15 (1.50%)
Ex-Dividend Date2019-07-12
1y Target EstN/A
  • 3 Top Diabetes Stocks to Watch in August
    Motley Fool

    3 Top Diabetes Stocks to Watch in August

    These three diabetes-oriented companies should be on your radar right now.

  • 10 Biggest Cancer-Fighting Stocks
    Motley Fool

    10 Biggest Cancer-Fighting Stocks

    The fight against cancer is a big battle. And these 10 companies are among the biggest combatants you can invest in.

  • 10 Biggest Medical Device Stocks
    Motley Fool

    10 Biggest Medical Device Stocks

    Market caps for these medical device stocks are big. Most of them have been big winners, too.

  • How to Invest in Medical Device Stocks
    Motley Fool

    How to Invest in Medical Device Stocks

    Here are seven simple steps to follow when considering investing in the fast-growing medical device industry.

  • Abbott Laboratories (ABT) Q2 2019 Earnings Call Transcript
    Motley Fool

    Abbott Laboratories (ABT) Q2 2019 Earnings Call Transcript

    ABT earnings call for the period ending June 30, 2019.

  • Abbott Stock Propelled Into Buy Zone As Medical Device Sales Fly
    Investor's Business Daily

    Abbott Stock Propelled Into Buy Zone As Medical Device Sales Fly

    Shares of Abbott Laboratories surged Wednesday after adjusted Abbott earnings topped Wall Street's expectations and the medical stock raised its sales and profit guidance for 2019.

  • Reuters

    US STOCKS-Wall St falls as railroads slide after CSX signals trade impact

    U.S. stock indexes retreated for the second day on Wednesday as weak results from CSX Corp pressured railroad stocks and highlighted the wide-ranging impact of the protracted trade war between the United States and China. Shares of CSX tumbled 10.7% and were set for their biggest one-day drop in nearly 17 years, after the company posted lower-than-expected quarterly profit and cut its full-year revenue forecast. Rival Union Pacific Corp slipped 5.7%, weighing heavily on the benchmark S&P 500 while Kansas City Southern fell 4.4%.

  • Wall Street falls as CSX results signal damage from trade tensions
    Reuters

    Wall Street falls as CSX results signal damage from trade tensions

    U.S. stock indexes fell on Wednesday as weak results from CSX Corp stoked concerns that the protracted trade war between the United States and China could hurt corporate earnings. shares tumbled 10.3%, their biggest one-day drop since 2008, after the rail freight company posted lower-than-expected quarterly profit and cut its full-year revenue forecast. Ongoing trade tensions have contributed to a decline in truck and rail freight volumes in the first half of 2019. The Federal Reserve's Beige Book, a compendium of anecdotes from U.S. businesses, also pointed to trade-related pressures on transportation and manufacturing companies.

  • Trending Stocks For July 16: CTAS, ABT, BK, HSY; What's Up With Utilities?
    Investor's Business Daily

    Trending Stocks For July 16: CTAS, ABT, BK, HSY; What's Up With Utilities?

    It may be a largely unchanged day for the broad stock market today, but there are plenty of stock and sector moves under the surface to watch.

  • Reuters

    Abbott hits record high as diabetes device fuels profit beat

    Abbott is betting on the device, FreeStyle Libre, and is working on newer versions to cushion slowing growth in some of its older products. The continuous glucose monitor, which helps diabetics track blood sugar levels without having to prick their fingers, is used by more than 1.5 million people worldwide. FreeStyle Libre 2, the next-generation device, which is already approved in Europe, is now under U.S. regulatory review.

  • Reuters

    UPDATE 2-Diabetes devices power Abbott's profit beat, forecast raise

    Abbott Laboratories beat analysts' estimates for quarterly profit and lifted its full-year adjusted earnings forecast on Wednesday, as the company benefits from strong demand for its blood sugar monitoring devices. Shares of the company, which also makes heart devices and nutritional products for babies and adults, rose about 2% to $84.75 in early trading. Sales of FreeStyle Libre, the company's continuous glucose monitor that helps diabetics track blood sugar levels without having to prick their fingers, surged 63.9% on a reported basis to $433 million in the second quarter.

  • TheStreet.com

    [video]Dow Ends Lower; S&P 500 Closes Below 3,000; CSX Tumbles

    Here Are 3 Hot Things to Know About Stocks Right Now The Dow Jones Industrial Average finished down over 100 points Wednesday as investors work through another day of earnings season. CSX shares fell after the third-largest U.

  • TheStreet.com

    Abbott Laboratories Hits Record High As FreeStyle Libre Sales Drive Q2 Earnings

    Abbott Laboratories posted stronger-than-expected second quarter earnings Wednesday, and boosted its full-year profit guidance, as sales of its FreeStyle Libre glucose monitoring system surged following FDA approval in 2017.

  • Reuters

    Abbott to hike production of lower-cost glucose monitors as diabetes soars

    Abbott Laboratories plans to ramp up manufacturing capacity for its lower-cost continuous glucose monitor, the FreeStyle Libre, by three to five times in the next few years, aiming to reach millions more patients worldwide, the company told Reuters. Abbott executives said the increase in manufacturing capacity will begin in the second half of this year and make room for the expected U.S. launch of the FreeStyle Libre 2. Abbott's plans for Libre, its fastest-growing diabetes product, used by 1.5 million people worldwide, will be in focus when the company reports quarterly earnings on Wednesday.

  • Reuters

    FOCUS- Abbott to hike production of lower-cost glucose monitors as diabetes soars

    Abbott Laboratories plans to ramp up manufacturing capacity for its lower-cost continuous glucose monitor, the FreeStyle Libre, by three to five times in the next few years, aiming to reach millions more patients worldwide, the company told Reuters. Abbott executives said the increase in manufacturing capacity will begin in the second half of this year and make room for the expected U.S. launch of the FreeStyle Libre 2. Abbott's plans for Libre, its fastest-growing diabetes product, used by 1.5 million people worldwide, will be in focus when the company reports quarterly earnings on Wednesday.

  • Morningstar

    The Week Ahead: Earnings Season Heats Up

    We're watching earnings from several wide- and narrow-moat companies, plus retail sales and housing starts.

  • The 10 Biggest Healthcare Stocks
    Motley Fool

    The 10 Biggest Healthcare Stocks

    How big does a company's market cap need to be to make the top 10 list of healthcare stocks? $111 billion.

  • Is Abbott Laboratories a Buy?
    Motley Fool

    Is Abbott Laboratories a Buy?

    This stock hasn't delivered much excitement, just great returns.

  • Where Will Abbott Laboratories Be in 10 Years?
    Motley Fool

    Where Will Abbott Laboratories Be in 10 Years?

    Expect the healthcare giant to hew to the principles that lifted it to where it stands now.

  • Reuters

    CORRECTED-Abbott device helps in cutting blood sugar in type 2 diabetics - study (June 8)

    Insulin-dependent patients with type 2 diabetes saw a significant drop in their blood sugar levels after wearing Abbott Laboratories Inc's continuous glucose monitoring system for three months compared with when they were not using the device, researchers said on Saturday. The study, which was presented at the American Diabetes Association meeting in San Francisco, assessed the medical records of 363 type 2 diabetics in France, Germany and Austria between three and six months. Dr. Helene Hanaire of the University Hospital Center of Toulouse, France, one of the study authors, said having ready access to their blood glucose readings helped diabetics become more engaged with controlling their glucose levels.

  • CNBC

    One sector is making a comeback amid market volatility

    Prepare for more churn around these levels, said  Mark Tepper , president of Strategic Wealth Partners. "We're really trying to target good companies that are big players in investible themes, and health care as a sector has struggled this year but it's been resilient over the past month. As the S&P 500 has tumbled 4% this month, the XLV health care sector ETF has held slightly positive.

  • 3 Dividend Aristocrats to Buy and Hold Forever
    Motley Fool

    3 Dividend Aristocrats to Buy and Hold Forever

    Stable businesses that dole out a regular paycheck are like a warm blankie for your portfolio.